Ocuphire Pharma Inc

NASDAQ:OCUPUnited States

Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its pipeline includes two small molecule product candidates targeting several of such indications. Nyxol Eye Drops (Nyxol) is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically induced mydriasis (RM), presbyopia (age-related blurry near vision) and dim light or night vision disturbances (DLD) (halos, glares and starbursts). Its product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases. The Company has also in-licensed APX2009 and APX2014, which are second-generation product candidates and analogs of APX3330.

Contact Information

Headquarters

37000 Grand River Ave., Suite 120FARMINGTON HILLS, MI, United States 48335

Phone

248-681-9815

Fax

240-268-5310

Executives

Independent Chairman of the Board

Cam Gallagher

Interim President, Chief Executive Officer, Director

Richard Rodgers

Senior Vice President - Finance

Amy Rabourn

Senior Vice President - Corporate Development and Operations

Bernhard Hoffmann

Lead Independent Director

Sean Ainsworth